Brief: Probi signs extensive primary care distribution agreement with Ipsen

Probi AB

26/04/2016 07:52

April 26 (Reuters) - Probi AB  PROB.ST : 
    * Probi and Ipsen sign extensive primary care distribution agreement for probiotic LP299V, 
Lactobacillus plantarum 299v 
    * Agreement covers 18 countries, primarily within EU and emerging markets 
    * Probi will supply bulk LP299V capsules and Ipsen will be responsible for packaging, 
marketing and selling product 
    * Product is expected to be launched in first half of 2017 as a food supplement in European 
markets 
    * Product is expected to be launched in other key markets such as Russia and China, 
depending on regulatory approval 
 
     
Source text for Eikon:  ID:nBw49DvmGa  
     
Further company coverage:  PROB.ST  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))